Oncologic and Reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 Adenocarcinoma: A systematic review

Gynecologic Oncology

Volumn 125, Issue 2, 2012, Pages 477-482

  Gunderson, Camille C ^a   Fader, Amanda Nickles ^a,b   Carson, Kathryn A ^c   Bristow, Robert E ^d  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b GREATER BALTIMORE MEDICAL CENTER   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Disease persistence; Endometrial carcinoma; Endometrial hyperplasia; Progestin therapy; Reproductive outcomes

Indexed keywords

GESTAGEN; HYDROXYPROGESTERONE; HYDROXYPROGESTERONE CAPROATE; LEVONORGESTREL; MEDROXYPROGESTERONE; MEGESTROL ACETATE; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE;

CANCER HORMONE THERAPY; CANCER PATIENT; DRUG RESPONSE; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FOLLOW UP; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; LIVE BIRTH; OUTCOME ASSESSMENT; PREGNANCY OUTCOME; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; FEMALE; FERTILITY PRESERVATION; HUMANS; PREGNANCY; PREGNANCY OUTCOME; PROGESTINS; TREATMENT OUTCOME;

EID: 84859583199     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.01.003     Document Type: Review

References (63)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 1984;64:417-20. (Pubitemid 14073467)
3. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009;105:103-4.
4. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and welldifferentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997;90:434-40. (Pubitemid 27357938)
5. Jobo T, Imai M, Kawaguchi M, Kenmochi M, Kuramoto H. Successful conservative treatment of endometrial carcinoma permitting subsequent pregnancy: report of two cases. Eur J Gynaecol Oncol 2000;21:119-22. (Pubitemid 30240591)
6. Ramirez PT, Frumovitz M, Bodurka DC, Sun CC, Levenback C. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol 2004;95:133-8. (Pubitemid 39286288)
7. Kim YB, Holschneider CH, Ghosh K, Nieberg RK, Montz FJ. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer 1997;79:320-7.
8. Kaku T, Yoshikawa H, Tsuda H, Sakamoto A, Fukunaga M, Kuwabara Y, et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. Cancer Lett 2001;167:39-48. (Pubitemid 32373267)
9. Gotlieb WH, Beiner ME, Shalmon B, Korach Y, Segal Y, Zmira N, et al. Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol 2003;102:718-25. (Pubitemid 37206407)
10. Wells GA, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.lri.ca/programs/ ceu/ oxford.htm.
11. Perri T, Korach J, Gotlieb WH, Beiner M, Meirow D, Friedman E, et al. Prolonged conservative treatment of endometrial cancer patients: more than 1 pregnancy can be achieved. Ann Oncol 2011;22:643-9.
12. Hahn HS, Yoon SG, Hong JS, Hong SR, Park SJ, Lim JY, et al. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol Cancer 2009;19:1068-73.
13. Yu M, Yang JX, Wu M, Lang JH, Huo Z, Shen K. Fertility-preserving treatment in young women with well-differentiated endometrial carcinoma and severe atypical hyperplasia of endometrium. Fertil Steril 2009;92:2122-4.
14. Eftekhar Z, Izadi-Mood N, Yarandi F, Shojaei H, Rezaei Z, Mohagheghi S. Efficacy of megestrol acetate (megace) in the treatment of patients with early endometrial adenocarcinoma: our experiences with 21 patients. Int J Gynecol Cancer 2009;19:249-52.
15. Signorelli M, Caspani G, Bonazzi C, Chiappa V, Perego P,Mangioni C. Fertility-sparing treatment in youngwomenwith endometrial cancer or atypical complex hyperplasia: a prospective single-institution experience of 21 cases. BJOG 2009;116:114-8.
16. Varma R, Soneja H, Bhatia K, Ganesan R, Rollason T, Clark TJ, et al. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia-a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol 2008;139:169-75.
17. Wildemeersch D, Janssens D, Pylyser K, De Wever N, Verbeeck G, Dhont M, et al. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up. Maturitas 2007;57:210-3. (Pubitemid 46771029)
18. Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 2007;25:2798-803. (Pubitemid 47123189)
19. Tjalma WAA, Janssens D, Wildemeersch D, Colpaert C, Watty K. Conservative management of atypical endometrial hyperplasia and early invasive carcinoma with intrauterine levonorgestrel: a progesterone receptor study. EJC Supplements 2004;2:93-4.
20. Cade TJ, Quinn MA, Rome RM, Neesham D. Progestogen treatment options for early endometrial cancer. BJOG 2010;117:879-84.
21. Yarali H, Bozdag G, Aksu T, Ayhan A. A successful pregnancy after intracytoplasmic
22. Yang YC, Wu CC, Chen CP, Chang CL, Wang KL. Reevaluating the safety of fertility-sparing hormonal therapy for early endometrial cancer. Gynecol Oncol 2005;99:287-93.
23. Ercan CM, Duru NK, SakinciM, Alanbay I, Karasahin KE, Baser I. Successful twin pregnancy achieved by assisted reproductive technology in a patient with polycystic ovary syndrome with complex atypical endometrial hyperplasia treated with levonorgestrel-releasing intrauterine system. Gynecol Endocrinol 2010;26:125-8.
24. Shamshirsaz AA, Withiam-Leitch M, Odunski K, Baker T, Frederick PJ, Lele S. Young patients with endometrial carcinoma selected for conservative management: a need for vigilance for synchronous ovarian carcinomas, a case report and literature review. Gynecol Oncol 2007;104:757-60. (Pubitemid 46240271)
25. Piura B. Two successful pregnancies after in vitro fertilization and embryo transfer in a patient with endometrial atypical hyperplasia bordering on adenocarcinoma treated conservatively with high-dose progesterone. Gynecol Obstet Invest 2006;61:21-3. (Pubitemid 43087546)
26. Rubatt JM, Slomovitz BM, Burke TW, Broaddus RR. Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia. Gynecol Oncol 2005;99:472-6. (Pubitemid 41502862)
27. Bozdag G, Yarali H, Polat M, Esinler I, Tiras B, Ayhan A. ICSI outcome following conservative fertility sparing management of endometrial cancer. Reprod Biomed Online 2009;18:416-20.
28. Wu HM, Lai CH, Huang HY, Wang HS, Soong YK. A successful live twin birth by in vitro fertilization after conservative treatment of recurrent endometrial cancer. Chang Gung Med J 2008;31:102-6. (Pubitemid 351453910)
29. Niwa K, Tagami K, Lian Z, Onogi K, Mori H, Tamaya T. Outcome of fertilitypreserving treatment in young women with endometrial carcinomas. BJOG 2005;112:317-20. (Pubitemid 40314007)
30. Qi X, Zhao W, Duan Y, Li Y. Successful pregnancy following insertion of a levonorgestrel-releasing intrauterine system in two infertile patients with complex atypical endometrial hyperplasia. Gynecol Obstet Invest 2008;65: 266-8. (Pubitemid 351793727)
31. Demirol A, Bahce M, Ayhan A, Gurgan T. Pregnancy following intracytoplasmic sperm injection and preimplantation genetic diagnosis after the conservative management of endometrial cancer. Reprod Biomed Online 2005;10:770-3. (Pubitemid 40796946)
32. Kresowick J, Ryan GL, Van Voorhis BJ. Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system. Obstet Gynecol 2008;111:547-9. (Pubitemid 351156496)
33. Yasuda M, Matsui N, Kajiwara H, Osamura RY, Miyamoto T, Murakami M, et al. Malignant transformation of atypical endometrial hyperplasia after progesterone therapy showing germ-cell tumor-like differentiation. Pathol Int 2004;54:451-6. (Pubitemid 38829933)
34. Yang YC, Wu CC, Chen CP, Chang CL, Wang KL. Reevaluating the safety of fertilitysparing hormonal therapy for early endometrial cancer. Gynecol Oncol 2005;99: 287-93.
35. Han AR, Kwon YS, Kim DY, Kim JH, Kim YM, Kim YT, et al. Pregnancy outcomes using assisted reproductive technology after fertility-preserving therapy in patients with endometrial adenocarcinoma or atypical complex hyperplasia. Int J Gynecol Cancer 2009;19:147-51.
36. Wheeler DT, Bristow RE, Kurman RJ. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am J Surg Pathol 2007;31:988-98. (Pubitemid 47012294)
37. Minaguchi T, Nakagawa S, Takazawa Y, Nei T, Horie K, Fujiwara T, et al. Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium. Cancer Lett 2007;248:112-22.
38. Park JC, Cho CH, Rhee JH. A successful live birth through in vitro fertilization program after conservative treatment of FIGO grade I endometrial cancer. J Korean Med Sci 2006;21:567-71. (Pubitemid 43926009)
39. Yamazawa K, Hirai M, Fujito A, Nishi H, Terauchi F, Ishikura H, et al. Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Hum Reprod 2007;22:1953-8. (Pubitemid 47062765)
40. Topuz S, Kalelioǧlu I, Iyibozkurt C, Ergun B. Conservative management of a patient with endometrial carcinoma desiring fertility: how to inform? Eur J Gynaecol Oncol 2008;29:661-3.
41. Vandenput I, Van Eygen K, Moerman P, Vergote I, Amant F. Ineffective attempt to preserve fertility with a levonorgestrel-releasing intrauterine device in a young woman with endometrioid endometrial carcinoma: a case report and review of the literature. Eur J Gynaecol Oncol 2009;30:313-6.
42. Sodano M, Bogliatto F, Morero S, Mosso L, Torchio B, Leidi L. Case report: successful IVF programme after conservatively treated endometrial cancer. Reprod Biomed Online 2009;18:578-81.
43. Hurst SA, Hartzfeld KM, Del Priore G. Occult myometrial recurrence after progesterone therapy to preserve fertility in a young patient with endometrial cancer. Fertil Steril 2008;89:724.e1-3.
44. Gurgan T, Bozdag G, Demirol A, Ayhan A. Preserving fertility before assisted reproduction in women with endometrial carcinoma: case report and literature review. Reprod Biomed Online 2007;15:561-5. (Pubitemid 350167079)
45. Chang WH, Chen CH, Yu MH. Conservative therapy of stage I endometrial adenocarcinoma and atypical endometrial hyperplasia for the preservation of fertility. Int J Gynaecol Obstet 2006;92:137-8. (Pubitemid 43098874)
46. Nakao Y, Nomiyama M, Kojima K, Matsumoto Y, Yamasaki F, Iwasaka T. Successful pregnancies in 2 infertile patients with endometrial adenocarcinoma. Gynecol Obstet Invest 2004;58:68-71. (Pubitemid 39140388)
47. Fambrini M, Bargelli G, Peruzzi E, Buccoliero AM, Pieralli A, Andersson KL, et al. Levonorgestrel-releasing intrauterine system alone as primary treatment in young women with early endometrial cancer: case report. Minim Invasive Gynecol 2009;16:630-3.
48. Ota T, Yoshida M, Kimura M, Kinoshita K. Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger. Int J Gynecol Cancer 2005;15:657-62. (Pubitemid 41022904)
49. Ferrandina G, Zannoni GF, Gallotta V, Foti E, Mancuso S, Scambia G. Progression of conservatively treated endometrial carcinoma after full term pregnancy: a case report. Gynecol Oncol 2005;99:215-7. (Pubitemid 41354604)
50. Dhar KK, NeedhiRajan T, Koslowski M, Woolas RP. Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecol Oncol 2005;97:924-7. (Pubitemid 40824667)
51. Takahashi N, Hirashima Y, Harashima S, Takekuma M, Kawaguchi R, Yamada Y, et al. A patient with stage 1a endometrial carcinoma in whom a solitary recurrent lesion was detected in the external iliac lymph node after MPA therapy. Arch Gynecol Obstet 2008;278:365-7.
52. Fujiwara H, Ogawa S, Motoyama M, Takei Y, Machida S, Taneichi A, et al. Frequency and characteristics of endometrial carcinoma and atypical hyperplasia detected on routine infertility investigations in young women: a report of six cases. HumReprod 2009;24:1045-50.
53. Cormio G, Martino R, Loizzi V, Resta L, Selvaggi L. A rare case of choroidal metastases presented after conservative management of endometrial cancer. Int J Gynecol Cancer 2006;16:2044-8. (Pubitemid 44924369)
54. Hoekstra AV, Kim JJ, Keh P, Schink JC. Absence of progesterone receptors in a failed case of fertility-sparing treatment in early endometrial cancer: a case report. J Reprod Med 2008;53:869-73.
55. Yahata T, Fujita K, Aoki Y, Tanaka K. Long-term conservative therapy for endometrial adenocarcinoma in young women. Hum Reprod 2006;21:1070-5.
56. Mao Y, Wan X, Chen Y, Lv W, Xie X. Outcomes of conservative therapy for young women with early endometrial adenocarcinoma. Fertil Steril 2010;93:283-5.
57. Kelley RM, Baker WH. Progestational agents in the treatment of carcinoma of the endometrium. N Engl J Med 1961;264:216-22.
58. Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke II JJ, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006;106:812-9. (Pubitemid 43238448)
59. Jadoul P, Donnez J. Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma. Fertil Steril 2003;80:1315-24.
60. Montz FJ, Bristow RE, Bovicelli A, Tomacruz R, Kurman RJ. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol 2002;186:651-7. (Pubitemid 34494341)
61. Walsh C, Holschneider C, Hoang Y, Tieu K, Karlan B, Cass I. Coexisting ovarianmalignancy in young women with endometrial cancer. Obstet Gynecol 2005;106:693-9. (Pubitemid 41362170)
62. Shen ZQ, Zhu HT, Lin JF. Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives. Obstet Gynecol 2008;112:465-7.
63. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6- month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000;85(1):139-46. (Pubitemid 32268804)